Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Gynecologic 1

Conditions

Endometrial Neoplasms 4Ovarian Neoplasms 3Neoplasms 2Recurrence 1Neoplasm Metastasis 1Glioblastoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 23Paclitaxel 14Cyclophosphamide 13Carboplatin 12Specimen Handling 10Magnetic Resonance Spectroscopy 10Biopsy 9fludarabine 8Nivolumab 7Leucovorin 7Gemcitabine 7Fluorouracil 7Doxorubicin 7aldesleukin 6Oxaliplatin 6Cisplatin 6liposomal doxorubicin 5Topotecan 5Taxes 5Irinotecan 5Interleukin-2 5olaparib 4atezolizumab 4Hyperthermic Intraperitoneal Chemotherapy 4Drug Therapy 4seribantumab 3fludarabine phosphate 3durvalumab 3dostarlimab 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × ridaforolimus × Gynecologic × Clear all
NCT01256268 2017-08-30

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
24 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡